St. Jude Medical Comments on MAUDE Database Report about Durata Lead


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


St. Jude Medical, Inc. (NYSE: STJ) today issued the following statement: Through our investigation of the MAUDE database report submitted to the FDA on May 2, 2012, and information provided to the company by the FDA, including model number, implant and event dates, St. Jude Medical has identified a single Durata® lead that matches the available information. The FDA has confirmed that the serial number of this lead matches the serial number from the MAUDE report. Our analysis of the lead indicates it was damaged due to external abrasion, which is not the same as the inside-out abrasion that has been seen in our previous generation Riata® leads. Simultaneous to this announcement, the company has submitted a medical device report (MDR) to the FDA with our additional findings. The identified lead was explanted at a Florida hospital, and the hospital has been very helpful in allowing the company to review the details of this case. The hospital has provided us with static and dynamic fluoroscopy and photographs of the extracted lead. The hospital also allowed us to inspect the lead at the hospital. One of our senior lead engineers traveled to the hospital to microscopically analyze the lead under the hospital's supervision. Through our investigation, we have identified that the patient had an additional defibrillation lead that had been capped (and was no longer being used). In the fluoroscopic images, the two leads cross in the region mentioned in the filed MAUDE report. Based upon physical examination, our analysis indicates the damage to the Durata lead is consistent with external abrasion from contact with a calcified, or hardened, heart valve or possibly from lead-to-lead contact. External abrasion is a known cause of failure across all cardiac leads in the industry, which is different from the inside-out abrasion seen with externalized conductors observed in some Riata leads. We recognize the importance of providing physicians with up-to-date and accurate information in a timely and responsible manner so that they can make informed patient care decisions. This case highlights the importance of appropriate analysis in determining the root cause of lead damage. It is our desire to work closely with physicians to understand the circumstances surrounding a device malfunction. We encourage physicians to report any case of lead failure to the manufacturer for further inspection and analysis to best ensure we are able to validate and communicate information in the interest of patient safety.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: News